ReviewFrontiers in immunology2020
The Inflammasome in Times of COVID-19.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06080750 (Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression In COVID-19 Patients), which is not on this map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression In COVID-19 Patients: Impact of Ferretin and D -Dimer.
Who cites it
72 citing papers in PubMed, 102 citations in OpenAlex.
- Using the reflux symptom index to quantify throat symptom burden in LPR-screened-negative patients before and during SARS-CoV-2 infection in China: a prospective follow-up study.Frontiers in medicine · 2026Article
- TNF/IFN-γ Co-Signaling Induces Differential Cellular Activation in COVID-19 Patients: Implications for Patient Outcomes.International journal of molecular sciences · 2025Article
- Chronic Corticosterone Administration-Induced Mood Disorders in Laboratory Rodents: Features, Mechanisms, and Research Perspectives.International journal of molecular sciences · 2024Review
- Article
- Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens.iScience · 2024Article
- Evaluation of the relationship between serum interleukin-1β levels and expression of inflammasome-related genes in patients with COVID-19.BMC immunology · 2023Article
- Immunomodulatory approaches in managing lung inflammation in COVID-19: A double-edge sword.Immunity, inflammation and disease · 2023Review
- Article
- Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variants.Journal of nanobiotechnology · 2023Review
- Nasopharyngeal epithelial cells from patients with coronavirus disease 2019 express abnormal levels of Toll-like receptors.Pathogens and global health · 2023Article
- Activation of inflammasomes and their effects on neuroinflammation at the microelectrode-tissue interface in intracortical implants.Biomaterials · 2023Article
- Photobiomodulation Reduces the Cytokine Storm Syndrome Associated with COVID-19 in the Zebrafish Model.International journal of molecular sciences · 2023Article
- NLRP3 Inflammasome's Activation in Acute and Chronic Brain Diseases-An Update on Pathogenetic Mechanisms and Therapeutic Perspectives with Respect to Other Inflammasomes.Biomedicines · 2023Review
- Article
- Inflammasome signaling proteins as biomarkers of COVID-19.Frontiers in immunology · 2023Article
- Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies.Frontiers in immunology · 2023Article
- Article
- Cytokine storm: behind the scenes of the collateral circulation after acute myocardial infarction.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Coagulation Profile of COVID-19 Patients.Life (Basel, Switzerland) · 2022Review
- Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach.International journal of molecular sciences · 2022Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Coronaviruses (CoVs) are members of the genus Betacoronavirus and the Coronaviridiae family responsible for infections such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and more recently, coronavirus disease-2019 (COVID-19). CoV infections present mainly as respiratory infections that lead to acute respiratory distress syndrome (ARDS). However, CoVs, such as COVID-19, also present as a hyperactivation of the inflammatory response that results in increased production of inflammatory cytokines such as interleukin (IL)-1β and its downstream molecule IL-6. The inflammasome is a multiprotein complex involved in the activation of caspase-1 that leads to the activation of IL-1β in a variety of diseases and infections such as CoV infection and in different tissues such as lungs, brain, intestines and kidneys, all of which have been shown to be affected in COVID-19 patients. Here we review the literature regarding the mechanism of inflammasome activation by CoV infection, the role of the inflammasome in ARDS, ventilator-induced lung injury (VILI), and Disseminated Intravascular Coagulation (DIC) as well as the potential mechanism by which the inflammasome may contribute to the damaging effects of inflammation in the cardiac, renal, digestive, and nervous systems in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.